Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65491 | 1.00 | HSD17B10 (0.63) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL77858 | 1.00 | HSD17B10 (0.63) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL222955 | 0.98 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL5898691 | 0.98 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL18358031 | 0.98 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL6219872 | 0.95 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL85536 | 0.95 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL67045 | 0.95 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL67044 | 0.95 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL27877016 | 0.95 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 905 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119977978-A | Catalytic synthesis method of chiral pyrazolo hydro-pyran compound | 中国海洋大学 | 2025-05-13 | — | — | CN | claimed |
| CN-118852326-A | PROTAC compound for targeted degradation of PI3K 110 beta and preparation method and application thereof | 河南大学 | 2024-10-29 | — | — | CN | claimed |
| CN-118255837-A | Method for synthesizing illegal stand | 苏州特瑞药业股份有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-115650903-B | Preparation method of initial amino acid Boc-Pip (Fmoc) -OH | 苏州天马医药集团天吉生物制药有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-115650903-A | Preparation method of initial amino acid Boc-Pip (Fmoc) -OH | 苏州天马医药集团天吉生物制药有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-101168514-B | Practical synthesis method for alpha-aminosuberate and alpha-amino suberic acid monoester with optical activity | SHANGHAI YAOMING KANGDE NEW MEDICINE DEVELOPMENT CO., LTD. (CN) | 2011-12-07 | — | — | CN | claimed |
| CN-101168514-A | Practical synthesis method for alpha-aminosuberate and alpha-amino suberic acid monoester with optical activity | SHANGHAI PHARMATECH CO LTD (CN) | 2008-04-30 | — | — | CN | claimed |
| CN-122036596-A | N- (2 ',6' -xylyl) -2-piperidine carboxamide derivative and application thereof | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | GIVAUDAN SA (CH) | 2026-04-16 | — | — | US | disclosed |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| WO-1994007858-A1 | 1-(2-OXO-ACETYL)-PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES AS MULTI-DRUG-RESISTENT CANCER CELL SENSITIZERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-04-14 | — | — | WO | disclosed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | disclosed |
| US-5235066-A | FK-506 type macrolide intermediate | MERCK & CO., INC. (US) | 1993-08-10 | — | — | US | disclosed |
| US-5164525-A | SYNTHETIC PROCESS FOR FK-506 TYPE MACROLIDE INTERMEDIATES | MERCK & CO., INC. (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0488301-A1 | New benzopyran compounds with pharmacological activity | J. URIACH & CIA. S.A. (ES) | 1992-06-03 | — | — | EP | disclosed |
| EP-0405994-A2 | Synthetic process for FK-506 type macrolide intermediates | MERCK & CO. INC. (US) | 1991-01-02 | — | — | EP | disclosed |
| EP-0310918-A2 | Peptide-like amino-acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | TRPM8, TRPM7, TRPM5 | HSD17B10 3385/4885SMN1; SMN2 2680/4885RAB9A 1602/4885 |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | HSD17B10 342/4885SMN1; SMN2 36/4885RAB9A 893/4885 |
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | CCR1, CCR6, CCRL2 | HSD17B10 2918/4885SMN1; SMN2 3318/4885RAB9A 1097/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | HSD17B10 1168/4885SMN1; SMN2 881/4885RAB9A 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.